Introduction/Overview
Natural products, as an important treasure trove for drug discovery and development, play an irreplaceable role in the long history of human fight against diseases. Among them, triterpenoid saponins have always been a hot topic in medicinal chemistry and pharmacology research due to their structural diversity and wide range of biological activities. Astragaloside III (CAS number: 84687-42-3) as a traditional tonic Chinese medicine, Astragalus membranaceus（Astragalus membranaceus An important triterpenoid saponin monomer isolated from (Fisch.) Bge. has gradually revealed its multifaceted pharmacological activities in recent years, demonstrating multidimensional therapeutic potential from anti-tumor, antiviral to neuroprotective effects. Especially its association with major disease-related targets such as cerebral infarction provides a scientific basis for its transition from traditional applications to modern precision therapy. This article aims to systematically review the chemical properties, plant sources, pharmacological activities, mechanisms of action, pharmacological evaluation, and clinical application prospects of Astragaloside III, in order to provide comprehensive academic references for the in-depth research and development of this compound.
Chemical structure and physicochemical properties
Astragaloside III belongs to the cycloaltane type tetracyclic triterpenoid saponins and is one of the main members of the Astragaloside class compounds. Its molecular formula is C41H68O14 and its molecular weight is 784.9810. Its basic skeleton is cycloaltenes, with sugar chains connected at C-3 and C-6 positions, which are key structural features for its biological activity. Common sugar groups include glucose, xylose, etc. The introduction of these hydrophilic sugar groups significantly affects their overall physicochemical properties.
From the analysis of parameters related to drug properties, the lipid water partition coefficient (LogP) of Astragaloside III is 2.2361, indicating that it has a certain degree of lipophilicity, but not high lipid solubility. Its topological polar surface area (TPSA) is as high as 228.2200 Å ², mainly attributed to the strong polarity brought by multiple hydroxyl and sugar structures in the molecule. High TPSA values are usually associated with poor membrane permeability. Its water solubility value is 0.0487, which belongs to slightly soluble or poorly soluble in water. This is not completely consistent with the characteristics of its saponin structure surfactant, indicating that it may form micelles or require specific solvent systems for solubility assistance. These physical and chemical properties collectively determine its poor membrane permeability, predicting its blood-brain barrier permeability as "low", which poses the primary challenge for its application in central nervous system diseases such as cerebral infarction. However, its hERG inhibition risk is' no ', and the Ames test result is 0.0, indicating a low risk of cardiac toxicity and genetic toxicity, providing favorable early data for its safety evaluation.
Plant sources and extraction methods
Astragaloside III is mainly derived from the leguminous plant Astragalus membranaceus（Astragalus membranaceus var. mongholicus (Bge.) Hsiao or Astragalus membranaceus（Astragalus membranaceus Dry roots of (Fisch.) Bge. Huangqi, as a vital tonic for qi, has a complex chemical composition. In addition to Huangqi saponin III, it also contains various saponins such as Huangqi saponins I, II, IV, as well as active ingredients such as Huangqi polysaccharides and flavonoids.
The efficient and specific extraction and isolation of Astragaloside III from Astragalus membranaceus medicinal materials is the basis for studying its activity. The commonly used extraction methods currently include:
1. Solvent extraction method The most commonly used method is to use different concentrations of ethanol or methanol for reflux extraction or ultrasound assisted extraction. Ethanol aqueous solution (such as 70% -80%) has become the preferred choice due to its good selectivity for saponins and low toxicity.
2. Purification method using macroporous resin After the crude extract is dispersed in water, non-polar or weakly polar macroporous adsorption resins (such as D101, AB-8) are commonly used for enrichment and purification. First, strong polar impurities such as polysaccharides are washed away with water, and then different concentrations of ethanol are used for gradient elution. Astragaloside III is usually obtained at the higher concentration ethanol elution site.
3. Chromatographic separation method To further obtain high-purity monomers, techniques such as silica gel column chromatography, reverse phase silica gel column chromatography (such as ODS), high performance liquid chromatography (HPLC), and preparative liquid chromatography are often used for fine separation. Modern technologies such as high-speed countercurrent chromatography (HSCCC) have also been applied to the separation of astragalus saponins due to their advantages of irreversible adsorption and high recovery rate.
The optimization goal of the extraction process is to improve the yield and purity of Astragaloside III, while maintaining its biological activity, providing quality controlled raw materials for subsequent pharmacological research and formulation development.
Pharmacological activity research
A large number of in vitro and in vivo studies have revealed the extensive pharmacological activities of Astragaloside III, mainly focusing on anti-tumor, antiviral, neuroprotective, and immune regulatory aspects.
-
Antitumor activity Research has confirmed that Astragaloside III has inhibitory effects on proliferation and induces apoptosis in various tumor cell lines. Its anti-cancer activity to breast cancer and colon cancer cells is particularly prominent. The effect is manifested as dose-dependent inhibition of cancer cell growth, cell cycle arrest (mostly occurring in G0/G1 or G2/M phases), and induction of mitochondrial pathway apoptosis (such as increasing Bax/Bcl-2 ratio, activating Caspase-3/9, etc.).
-
Antiviral activity Huangqi Saponin III exhibits antiviral activity against Dengue virus serotypes 1 and 3. Its mechanism of action may involve interfering with the lifecycle of the virus, such as inhibiting virus adsorption, invasion, or intracellular replication, but its specific action steps still need to be further studied. This provides clues for the development of new natural medicines against dengue virus infection.
-
Neuroprotection and anti cerebral ischemia activity Research on cerebral infarction (ischemic stroke) is an emerging hotspot in the pharmacological study of Astragaloside III. Animal model studies have shown that pre-treatment or post-treatment with Astragaloside III can alleviate cerebral ischemia-reperfusion injury, manifested as reducing cerebral infarction volume, improving neurological deficit scores, and reducing brain edema. Its protective effect is closely related to antioxidant stress, inhibition of inflammatory response, and anti neuronal apoptosis.
-
Immune regulatory activity Huangqi saponin III can increase the expression of natural killer (NK) cell surface activating receptor NKG2D. NKG2D is a key receptor for NK cells and some T cells to recognize and kill diseased cells. Upregulation of NKG2D may enhance the body's immune surveillance and ability to clear abnormal cells, such as tumor cells and virus-infected cells. In addition, its induction of TACE (tumor necrosis factor alpha converting enzyme) phosphorylation suggests that it may be involved in regulating immune inflammatory processes such as the release of inflammatory factor TNF - α.
Mechanism of action and molecular targets
The multiple pharmacological effects of Astragaloside III stem from its regulation of multiple signaling pathways within cells and its effects on specific molecular targets. Combined with its known activity, especially targets related to cerebral infarction, its mechanism of action network is gradually becoming clearer.
-
Regulating apoptosis related pathways The induction of tumor cell apoptosis by Astragaloside III is the core mechanism of its anti-cancer activity. It activates the Caspase cascade reaction by regulating Bcl-2 family proteins (upregulation of pro apoptotic Bax and downregulation of anti apoptotic Bcl-2), inducing depolarization of mitochondrial membrane potential, promoting cytochrome C release, and ultimately leading to cell apoptosis. In cerebral ischemic injury, it exerts neuroprotective effects by inhibiting the above-mentioned apoptotic pathways.
-
Intervention in inflammation and oxidative stress signaling In the cerebral infarction model, the effect of Astragaloside III is related to multiple key targets:
- STAT3 Signal transducer and activator of transcription factor 3 is an important inflammatory and survival signaling hub. Huangqi saponin III may alleviate neuroinflammation after ischemia by inhibiting abnormal activation of STAT3, downregulating the expression of downstream pro-inflammatory factors such as IL-6 and TNF - α.
- SIRT1 Silent information regulatory factor 1 is an NAD+- dependent deacetylase involved in regulating cellular stress response, metabolism, and aging. Activation of the SIRT1 pathway has neuroprotective effects. Huangqi saponin III may enhance antioxidant capacity, inhibit inflammation and apoptosis by upregulating or activating SIRT1, deacetylating and inhibiting the activity of proteins such as p53 and NF - κ B.
- APP/β - amyloid (A β) pathway Abnormal metabolism of amyloid precursor protein is associated with secondary damage and dementia after cerebral ischemia. Huangqi saponin III may reduce the production of neurotoxic A β and alleviate amyloid protein pathological damage after ischemia by regulating APP processing.
- BCHE (butyrylcholinesterase) and EPHX2 (soluble epoxide hydrolase)These two enzymes are respectively involved in cholinergic neurotransmission and the metabolism of anti-inflammatory epoxyeicosaenoic acid (EETs). Inhibition of BCHE may enhance cholinergic anti-inflammatory effects, while inhibition of EPHX2 can increase the levels of endogenous anti-inflammatory substances EETs, jointly alleviating post ischemic inflammatory damage.
-
Regulating immune cell function By upregulating NKG2D receptors on NK cells and cytotoxic T cells, Astragaloside III enhances the recognition and killing ability of these effector cells towards "stress-induced" or "pathological" cells, which is an important mechanism for its anti-tumor and potential antiviral immunity.
-
Affects enzyme activity Inducing phosphorylation of TACE (ADAM17) may alter the activity of its cleavage substrates (such as TNF - α and TNF receptors), thereby finely regulating tumor necrosis factor mediated inflammation and cell survival signals.
Evaluation of drug properties and pharmacokinetics
Despite the significant pharmacological activity of Astragaloside III, there are significant challenges in its drug likeness, which directly affects its translation into clinical applications.
-
Absorption, distribution, metabolism, excretion (ADME)：
- absorb Due to its high molecular weight, high TPSA, limited water solubility, and poor passive transmembrane diffusion ability, its oral bioavailability is expected to be low. Research has shown that the absorption of total saponins or monomeric saponins of Astragalus membranaceus is slow and incomplete after oral administration, and may require deglycosylation to convert them into secondary glycosides or aglycones under the action of gut microbiota before they can be absorbed.
- distribution The predicted low blood-brain barrier permeability is the main obstacle to its treatment of central nervous system diseases. The key to research is how to improve its brain distribution through formulation techniques such as nano drug delivery systems, prodrug strategies, or combination therapy.
- Metabolism and excretion Saponins are mainly metabolized by the liver in the body and may involve reactions such as hydrolysis, oxidation, and binding. The prototype drug and its metabolites are mainly excreted through bile and kidneys. At present, there is insufficient research on the detailed metabolic profile and main metabolic enzymes of Astragaloside III.
-
Pharmaceutical Science Challenge To improve its solubility and bioavailability, it is necessary to develop new drug delivery systems. The current research directions include: preparing it into phospholipid complexes, cyclodextrin inclusion complexes, solid dispersions, liposomes, nanoparticles (such as polymer nanoparticles, mesoporous silica nanoparticles), etc. These technologies aim to increase its solubility, protect it from premature degradation, promote its transmembrane transport and targeted delivery.
-
Preliminary evaluation of safety The existing data (hERG negative, Ames negative) suggest good early safety signals. However, comprehensive preclinical safety evaluation, including acute toxicity, chronic toxicity, reproductive toxicity, etc., is still an indispensable part of its new drug development.
Clinical application prospects and prospects
The transition of Huangqi Saponin III from laboratory research to clinical application has broad prospects, but the road is tortuous and requires interdisciplinary collaboration.
-
Potential indications：
- neoadjuvant therapy As an adjuvant treatment drug for breast cancer, colon cancer and other malignant tumors, combined with chemotherapy and radiotherapy may play a role in reducing toxicity and increasing efficiency. Its immune regulatory properties (enhancing NK cell activity) are particularly noteworthy.
- Ischemic stroke As a neuroprotective agent, it is an attractive direction for the acute or recovery treatment of cerebral infarction. But the challenge of blood-brain barrier delivery must be overcome.
- Antiviral infection Further validation of animal infection models and mechanisms is needed for the treatment or adjuvant therapy of viral diseases such as dengue fever.
- Other Based on its antioxidant and anti-inflammatory properties, it also has exploratory value in cardiovascular protection and anti-aging related diseases.
-
Future research directions：
- In depth mechanism exploration Using omics techniques (proteomics, metabolomics) and gene editing tools, systematically elucidate its multi-target action network, especially the dominant mechanisms under different pathological conditions.
- Structural optimization and derivative development To address its pharmacological shortcomings, reasonable chemical structural modifications should be made, such as simplifying sugar chains and introducing specific functional groups, in order to improve its pharmacokinetic properties while maintaining its activity.
- Advanced drug delivery system research and development Focus on developing intelligent nano drug delivery systems that can target lesion sites (such as tumors and ischemic brain areas), achieve precise and controllable release, improve efficacy, and reduce systemic toxicity.
- Preclinical and clinical research Complete preclinical pharmacological, pharmacokinetic, and safety evaluations of the system specifications to provide solid data for clinical trial applications. Explore clinical plans for its use as a monomer in traditional Chinese medicine or in combination with existing drugs.
Conclusion
Huangqi saponin III, as an active triterpenoid saponin derived from traditional Chinese medicine Huangqi, has become a highlight molecule in natural product pharmacology research due to its multiple pharmacological activities such as anti-tumor, antiviral, neuroprotective, and immune regulation. Its mechanism of action involves the regulation of multiple pathways such as apoptosis, inflammation, and oxidative stress, and interacts with multiple disease-related targets such as APP, STAT3, SIRT1, reflecting the multi-target and multi pathway characteristics of natural products. However, its poor drug properties, especially low solubility and blood-brain barrier permeability, are the main bottlenecks restricting its clinical application. Future research should focus on elucidating its precise target and signal network through chemical biology methods, and using modern pharmacy and nanotechnology to overcome its delivery challenges. Only by deeply integrating traditional wisdom with modern technology can the therapeutic potential of Astragaloside III be fully unleashed, providing more valuable candidate molecules for the development of new drugs targeting major diseases such as tumors, stroke, and viral infections.
